Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The primary purpose of this study is to establish if a 10.8 mg dose of ZOLADEX given 3 monthly is non-inferior to a 3.6 mg dose of ZOLADEX given monthly in terms of oestradiol suppression in patients with oestrogen receptor positive early breast cancer.
Epistemonikos ID: 4d6c3e41527da5c9fd13ecb0f3d1b6d854ddbc05
First added on: May 04, 2024